Moderna's Q1 Revenues Rocket, Thanks to Ex-US Sales

Why It Matters

The rebound signals Moderna’s successful pivot from a U.S.-centric COVID‑vaccine slump to a diversified global revenue base, laying groundwork for sustained growth and broader mRNA platform adoption.

Key Takeaways

• Q1 revenue jumped to $389 million, 80% from non‑US markets.
• US sales rose to $80 million, up from $29 million a year earlier.
• Company forecasts 10% growth in 2024, targeting 50% US share by 2026.
• New mRNA products mNEXSPIKE and mCombriax expected to boost pipeline.
• Shares gained over 6% after earnings beat expectations.

Pulse Analysis

Moderna’s latest earnings underscore a strategic shift toward international markets, now accounting for the bulk of its revenue. After a steep decline from a 2022 peak of nearly $20 billion, the company’s Q1 sales surged to $389 million, driven by long‑term vaccine supply contracts with governments such as the United Kingdom. The U.S. environment remains challenging, with reduced federal funding and heightened vaccine skepticism, yet domestic sales still more than doubled year‑over‑year, hinting at a gradual market re‑equilibration.

The pipeline is a key catalyst for future growth. Moderna is positioning its next‑generation COVID‑19 candidate, mNEXSPIKE, alongside the first‑in‑class flu/COVID‑19 combination shot, mCombriax, which secured European Commission approval in April and is under review in Canada and Australia. Additional readouts slated for 2024 include a melanoma immunotherapy partnership with MSD, a trivalent norovirus vaccine, and a rare‑disease therapy for propionic acidaemia. These developments diversify revenue streams beyond the pandemic‑era product and reinforce Moderna’s claim to be a leading mRNA platform company.

Investors responded positively, with the stock climbing over 6% after the results beat expectations. The company’s guidance—10% revenue growth this year and a target of 50% U.S. contribution by 2026—suggests confidence in both market recovery and pipeline execution. For the broader biotech sector, Moderna’s turnaround illustrates how mRNA innovators can leverage global demand, strategic partnerships, and an expanding product suite to offset domestic headwinds and sustain long‑term valuation growth.